Claims
- 1. A method of constructing a compound capable of eliciting in a mammal, a neutralizing immune response against a pathogen comprising the steps of:
a) generating a neutralizing antibody specific for an epitope of an antigen of said pathogen; b) generating an anti-idiotypic antibody specific for said neutralizing antibody; c) comparing amino acid sequences of said anti-idiotypic antibody and said epitope; and d) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said epitope.
- 2. The method of claim 1 further comprising:
e) synthesizing a peptide comprising an amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said epitope.
- 3. The method of claim 1 wherein said pathogen is a reovirus and said antigen is a haemagluttin sigma 1.
- 4. The method of claim 1 wherein said pathogen is HIV and said antigen is a gp120.
- 5. The method of claim 1 wherein said amino acid sequence of said anti-idiotypic antibody is an amino acid sequence of a complementarity determining region.
- 6. The method of claim 2 further comprising the step of:
modifying said synthesized peptide to alter the three dimensional conformation thereof; and/or modifying synthetic peptides by attaching connectors thereto and maintaining said synthetic peptides under conditions selected to allow formation of peptide dimers.
- 7. A method of constructing a compound capable of preventing a biologically active protein or a pathogen from binding to a receptor which comprises the steps of:
a) generating an anti-receptor antibody capable of preventing said biologically active protein or said pathogen from binding to said receptor; b) comparing amino acid sequences of said anti-receptor antibody and said biologically active protein or an antigen of said pathogen; and c) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said biologically active protein or said antigen of said pathogen.
- 8. The method of claim 7 further comprising:
d) synthesizing a peptide comprising an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said biologically active protein or said antigen of said pathogen.
- 9. The method of claim 7 wherein said pathogen is a reovirus and said receptor is a beta-adrenergic receptor-like structure which binds to haemagluttin and said antigen is a reovirus haemagluttin sigma 1.
- 10. The method of claim 7 wherein said pathogen is HIV, said receptor is a CD4 molecule and said antigen is a gp120.
- 11. The method of claim 7 wherein said amino acid sequence of said anti-receptor antibody is an amino acid sequence of a complementarity determining region.
- 12. The method of claim 8 further comprising the step of:
modifying said synthesized peptide to alter the three dimensional conformation thereof; and/or modifying synthetic peptides by attaching connectors thereto, and maintaining said synthetic peptides under conditions selected to allow formation of peptide dimers.
- 13. A method of constructing a compound capable of preventing a pathogen or a biologically active protein from binding to a receptor which comprises the steps of:
a) generating an antibody specific for said biologically active protein or an antigen of said pathogen, said antibody being capable of preventing said biologically active protein or said pathogen from binding to said receptor; b) generating an anti-idiotypic antibody specific for said antibody; c) comparing amino acid sequences of said anti-idiotypic antibody and said biologically active protein or said antigen; and d) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said biologically active protein or said antigen.
- 14. The method of claim 13 further comprising:
e) synthesizing a peptide comprising said amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said biologically active protein or said antigen.
- 15. The method of claim 13 wherein said pathogen is a reovirus and said receptor is a beta-adrenergic receptor-like structure which binds to haemagluttin and said antigen is a haemagluttin sigma 1.
- 16. The method of claim 13 wherein said pathogen is HIV, said receptor is a CD4 molecule and said antigen is a gp120.
- 17. The method of claim 13 wherein said amino acid sequence of said anti-idiotypic antibody is an amino acid sequence of a complementarity determining region.
- 18. The method of claim 14 further comprising the step of:
modifying said synthesized peptide and altering its three dimensional conformation; and/or, modifying synthetic peptides by attaching connectors thereto, and maintaining said synthetic peptides under conditions selected to allow formation of peptide dimers.
- 19. A method of constructing a biologically active compound comprising the steps of:
a) generating an anti-receptor antibody capable of effecting an activity or function of a cell; b) comparing amino acid sequences of said anti-receptor antibody and an antigen which binds to said receptor or a biologically active protein which binds to said receptor; and c) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said antigen or an amino acid sequence of said biologically active protein.
- 20. The method of claim 19 further comprising:
e) synthesizing a peptide comprising an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said antigen or an amino acid sequence of said biologically active protein.
- 21. The method of claim 19 wherein said antigen is from a reovirus and said receptor is a beta-adrenergic receptor-like structure which binds to haemagluttin and said antigen is a haemagluttin sigma 1.
- 22. The method of claim 19 wherein said amino acid sequence of said anti-receptor antibody is an amino acid sequence of a complementarity determining region.
- 23. The method of claim 20 further comprising the step of:
modifying said synthesized peptide and altering its three dimensional conformation; and or, modifying synthetic peptides by attaching connectors thereto and, maintaining said synthetic peptides under conditions selected to allow formation of peptide dimers.
- 24. A synthetic biologically active peptide consisting essentially of an amino acid sequence corresponding to an amino acid sequence of an anti-idiotypic antibody or an anti-receptor antibody and also corresponding to an amino acid sequence of an antigen or biologically active protein.
- 25. The peptide of claim 24 wherein said antigen is from a haemagluttin sigma 1 from a reovirus.
- 26. The peptide of claim 24 wherein said antigen is gp120 from HIV.
- 27. The peptide of claim 24 wherein said amino acid sequence of an anti-idiotypic antibody or anti-receptor antibody is an amino acid sequence of a complementarity determining region.
- 28. The peptide of claim 24 comprising an amino acid sequence selected from the group consisting of:
- 29. The peptide of claim 24 wherein said peptide has an amino acid sequence consisting essentially of:
- 30. The peptide of claim 24 comprising an amino acid sequence selected from the group consisting of:
- 31. The peptide of claim 24 having an amino acid sequence consisting essentially of:
- 32. The peptide of claim 24 wherein said peptide is a dimer comprising a first peptide sequence and a second peptide sequence, wherein:
said first peptide sequence and said second peptide sequence may be the same or different; each of said first peptide sequence and said second peptide sequence are identical or similar to similar portions of an antigen and an anti-idiotypic antibody for said antigen; and, said dimer is joined at one end.
- 33. The peptide of claim 24 wherein said peptide is a dimer comprising a first peptide sequence and a second peptide sequence, wherein:
said first peptide sequence and said second peptide sequence may be the same or different; each of said first peptide sequence and said second peptide sequence are identical or similar to similar portions of an antigen and an anti-idiotypic antibody for said antigen; and, said dimer is joined at one end by a sulfhydryl bond.
- 34. The peptide dimer of claim 24 wherein said peptide is a dimer comprising a first peptide sequence and a second peptide sequence, wherein:
said first peptide sequence and said second peptide sequence may be the same or different; each of said first peptide sequence and said second peptide sequence are identical or similar to similar portions of an antigen and an anti-idiotypic antibody for said antigen; said dimer is joined at one end; and said first peptide sequence comprises an amino acid sequence selected from the group consisting of: 11Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln, andCys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln;and said second peptide sequences comprises an amino acid sequence selected from the group consisting of: 12Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln, andCys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln.
- 35. A method of immunizing a host mammal against infection by a pathogen comprising the steps of:
a) generating a neutralizing antibody specific for an epitope of an antigen of said pathogen; b) generating an anti-idiotypic antibody specific for said neutralizing antibody; c) comparing amino acid sequences of said anti-idiotypic antibody and said epitope; d) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said epitope; e) synthesizing a peptide comprising an amino acid sequence that corresponds to an amino acid sequence of said anti-idiotypic antibody and also corresponds to an amino acid sequence of said epitope; and, f) inoculating said mammal with said synthetic peptide in an amount effective to reduce the likelihood that said host will be susceptible to infection by said pathogen.
- 36. The method of claim 35 wherein said pathogen is a reovirus.
- 37. The method of claim 35 wherein said synthetic peptide comprises the amino acid sequence selected from the group consisting of:
- 38. The method of claim 36 wherein said peptide is a dimer comprising a first peptide sequence and a second peptide sequence,
said first peptide sequence comprising an amino acid sequence selected from the group consisting of: 14Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln; andCys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln;and said second peptide sequences comprising an amino acid sequence selected from the group consisting of: 15Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln; andCys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln.
- 39. A method of treating a host mammal to prevent or reduce the severity of an infection by a pathogen comprising the steps of:
a) generating an anti-receptor antibody against a receptor which said pathogen binds to in infection, said anti-receptor antibodies capable of preventing said pathogen from binding to said receptor; b) comparing amino acid sequences of said anti-receptor antibody and said an antigen of said pathogen; c) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said antigen; d) synthesizing a peptide comprising said amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said antigen; e) inoculating said mammal with said synthetic peptide in an amount effective to prevent or reduce the likelihood of said pathogen infecting cells of said host.
- 40. The method of claim 39 wherein said pathogen is a reovirus.
- 41. The method of claim 39 wherein said synthetic peptide comprises the amino acid sequence selected from the group consisting of:
- 42. The method of claim 39 wherein said peptide is a dimer which comprises a first peptide sequence and a second peptide sequence,
said first peptide sequence comprising an amino acid sequence selected from the group consisting of: 17Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln; and,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln;and said second peptide sequences comprises an amino acid sequence selected from the group consisting of: 18Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Phe-Ser-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ala-Gly-Ser-Thr-Leu-Gln;Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Ala-Ser-Thr-Leu-Gln; and,Cys-Lys-Pro-Gly-Lys-Thr-Asn-Lys-Leu-Leu-Ile-Tyr-Ser-Gly-Ser-Ala-Leu-Gln.
- 43. A method of effecting or altering activity or function of a mammalian cell comprising:
a) generating an anti-receptor antibody capable of effecting an activity or function of said cell; b) comparing amino acid sequences of said anti-receptor antibody and a biologically active protein which can bind to said receptor and effect an activity or function of said cell; and c) determining an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said biologically active protein; d) synthesizing a peptide comprising an amino acid sequence that corresponds to an amino acid sequence of said anti-receptor antibody and also corresponds to an amino acid sequence of said biologically active protein; e) contacting said cell with said synthesized peptide, said synthetic peptide being present in an amount effective to effect or alter activity or function of said cell.
- 44. The method of claim 43 wherein said biologically active protein is an antigen of a pathogen.
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This Application is a Continuation of U.S. patent application Ser. No. 08/752,816, filed Nov. 21, 1996, allowed, which is a Continuation of U.S. patent application Ser. No. 07/940,654, filed Sep. 3, 1992, which issued as U.S. Pat. No. 5,637,677, which is a Continuation-In-Part Application of U.S. patent application Ser. No. 07/702,833, filed May 20, 1991, abandoned, which is a Continuation Application of U.S. patent application Ser. No. 07/326,328, filed Mar. 21, 1989, abandoned, which was a Continuation-In-Part Application of U.S. patent application Ser. No. 07/074,264, filed Jul. 16, 1987, abandoned. This Application is a Continuation-In-Part Application of U.S. patent application Ser. No. 07/462,542, filed Jan. 9, 1990, abandoned, which is a Divisional Application of U.S. patent application Serial Number 07/074,264, filed Jul. 16, 1987, abandoned. This Application is a Continuation-In-Part Application of U.S. patent application Ser. No. 07/648,303, filed Jan. 25, 1991, abandoned, which is a File Wrapper Continuation Application of U.S. patent application Ser. No. 07/074,264, filed Jul. 16, 1987, abandoned. This Application is a Continuation-In-Part Application of U.S. patent application Ser. No. 07/685,881, filed Apr. 15, 1991, abandoned, which is a Continuation Application of U.S. patent application Ser. No. 07/574,391, filed Aug. 27, 1990, abandoned which was a File Wrapper Continuation Application of U.S. patent application Ser. No. 07/194,026 filed May 13, 1988, abandoned, which was a Continuation-In-Part Application of U.S. patent application Ser. No. 07/074,264, filed Jul. 16, 1987, abandoned. This Application is a Continuation-In-Part Application of U.S. patent application Ser. No. 07/583,626, filed Sep. 14, 1990, abandoned. Each of the above listed patent applications is incorporated herein by reference.
ACKNOWLEDGMENT OF GOVERNMENT RIGHTS
[0002] This invention was made with Government support under Grant 5R01EY08191 awarded by the National Institutes of Health. The Government has certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
07074264 |
Jul 1987 |
US |
Child |
07462542 |
Jan 1990 |
US |
Continuations (6)
|
Number |
Date |
Country |
Parent |
08752816 |
Nov 1996 |
US |
Child |
10105545 |
Mar 2002 |
US |
Parent |
07940654 |
Sep 1992 |
US |
Child |
08752816 |
Nov 1996 |
US |
Parent |
07326328 |
Mar 1989 |
US |
Child |
07702833 |
May 1991 |
US |
Parent |
07074264 |
Jul 1987 |
US |
Child |
07648303 |
Jan 1991 |
US |
Parent |
07574391 |
Aug 1990 |
US |
Child |
07685881 |
Apr 1991 |
US |
Parent |
07194026 |
May 1988 |
US |
Child |
07574391 |
Aug 1990 |
US |
Continuation in Parts (7)
|
Number |
Date |
Country |
Parent |
07702833 |
May 1991 |
US |
Child |
07940654 |
Sep 1992 |
US |
Parent |
07074264 |
Jul 1987 |
US |
Child |
07326328 |
Mar 1989 |
US |
Parent |
07462542 |
Jan 1990 |
US |
Child |
10105545 |
Mar 2002 |
US |
Parent |
07648303 |
Jan 1991 |
US |
Child |
10105545 |
Mar 2002 |
US |
Parent |
07685881 |
Apr 1991 |
US |
Child |
10105545 |
Mar 2002 |
US |
Parent |
07074264 |
Jul 1987 |
US |
Child |
07194026 |
May 1988 |
US |
Parent |
07583626 |
Sep 1990 |
US |
Child |
10105545 |
Mar 2002 |
US |